quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 16, 2026

Zacks Investment Ideas feature highlights: Taiwan Semiconductor, NVIDIA, Apple, Broadcom and Meta Platforms

View original at finance.yahoo.com
Zacks Investment Ideas feature highlights: Taiwan Semiconductor, NVIDIA, Apple, Broadcom and Meta Platforms For Immediate Release Chicago, IL – January 16, 2026 – Today, Zacks Investment Ideas feature highlights Taiwan Semiconductor TSM, NVIDIA NVDA, Apple AAPL, Broadcom AVGO and Meta Platforms META…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • For advanced nodes (3nm and 5nm), current demand is roughly three times higher than available capacity

    80% confidence
  • Early interest for A16 from HPC and AI customers is extremely high

    80% confidence
  • Our pricing will remain strategic, not opportunistic

    80% confidence
  • Gross profit margin expected between 63% and 65% for Q1 2026

    80% confidence
  • CoWoS capacity is sold out through at least mid-2026

    80% confidence
  • Q1 2026 revenue will fall between $34.6 and $35.8 billion

    80% confidence
  • AI infrastructure buildout will cross $1 trillion annually in 2028

    80% confidence
  • AI infrastructure buildout will cross $1 trillion annually in 2028, with as much as 1/3 going for chips

    80% confidence
  • It takes two to three years to build a new fab and new capacity won't meaningfully help supply until 2028 or 2029

    80% confidence
  • TSM shares can go to $500 in 2027

    80% confidence
  • 2nm revenue will surpass the total of 3nm and 5nm by Q3 2026

    80% confidence
  • Buy TSM shares under $350

    80% confidence
  • Aggressive investment reflects sustained AI-driven demand and tight supply conditions

    80% confidence
  • A16 node remains on track for volume production in the second half of 2026

    80% confidence
  • Operating profit margin expected between 54% and 56% for Q1 2026

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com